Table 7.
Five-Year Total, Annual Average Totala, and Average Annual Age-Adjusted Incidence Ratesb with 95% Confidence Intervals of All Brain and Other Central Nervous System Tumors by Histology, and NCI Age at Diagnosis Groups, CBTRUS Statistical Report: U.S. Cancer Statistics – NPCR and SEER, 2014–2018
| Histology | Childrenc (0–14) | AYAd (15–39) | Older Adults (40+) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5-Year Total | Annual Average | Rate (95% CI) | 5-Year Total | Annual Average | Rate (95% CI) | 5-Year Total | Annual Average | Rate (95% CI) | |
| Diffuse Astrocytic and Oligodendroglial Tumors | 1,514 | 303 | 0.50 (0.47–0.52) | 9,791 | 1,958 | 1.84 (1.81–1.88) | 71,819 | 14,364 | 8.73 (8.66–8.79) |
| Diffuse astrocytoma | 685 | 137 | 0.22 (0.21–0.24) | 2,562 | 512 | 0.47 (0.46–0.49) | 4,482 | 896 | 0.58 (0.56–0.59) |
| Anaplastic astrocytoma | 250 | 50 | 0.08 (0.07–0.09) | 1,965 | 393 | 0.37 (0.35–0.38) | 4,960 | 992 | 0.63 (0.61–0.65) |
| Glioblastoma | 461 | 92 | 0.15 (0.14–0.17) | 2,920 | 584 | 0.56 (0.54–0.58) | 58,318 | 11,664 | 6.97 (6.91–7.03) |
| Oligodendroglioma | 78 | 16 | 0.03 (0.02–0.03) | 1,456 | 291 | 0.28 (0.26–0.29) | 2,172 | 434 | 0.30 (0.29–0.31) |
| Anaplastic oligodendroglioma | -- | -- | -- | -- | -- | -- | 1,331 | 266 | 0.18 (0.17–0.19) |
| Oligoastrocytic tumors | -- | -- | -- | -- | -- | -- | 556 | 111 | 0.07 (0.07–0.08) |
| Other Astrocytic Tumors | 3,626 | 725 | 1.19 (1.15–1.23) | 1,838 | 368 | 0.34 (0.32–0.35) | 749 | 150 | 0.10 (0.10–0.11) |
| Pilocytic astrocytoma | 3,250 | 650 | 1.07 (1.03–1.10) | 1,463 | 293 | 0.27 (0.26–0.28) | 590 | 118 | 0.08 (0.08–0.09) |
| Unique astrocytoma variants | 376 | 75 | 0.12 (0.11–0.14) | 375 | 75 | 0.07 (0.06–0.08) | 159 | 32 | 0.02 (0.02–0.03) |
| Malignant | 146 | 29 | 0.05 (0.04–0.06) | 270 | 54 | 0.05 (0.04–0.06) | 128 | 26 | 0.02 (0.01–0.02) |
| Non-Malignant | 230 | 46 | 0.08 (0.07–0.09) | 105 | 21 | 0.02 (0.02-0.02) | 31 | 6 | 0.00 (0.00–0.01) |
| Ependymal Tumors | 941 | 188 | 0.31 (0.29–0.33) | 1,922 | 384 | 0.36 (0.34–0.38) | 4,063 | 813 | 0.53 (0.51–0.55) |
| Malignant | 835 | 167 | 0.27 (0.25–0.29) | 1,024 | 205 | 0.19 (0.18–0.20) | 2,108 | 422 | 0.28 (0.26–0.29) |
| Non-Malignant | 106 | 21 | 0.03 (0.03–0.04) | 898 | 180 | 0.17 (0.16–0.18) | 1,955 | 391 | 0.25 (0.24–0.26) |
| Other Gliomas | 2,658 | 532 | 0.87 (0.84–0.91) | 1,832 | 366 | 0.34 (0.32–0.36) | 4,085 | 817 | 0.52 (0.50–0.54) |
| Glioma malignant, NOS | 2,632 | 526 | 0.86 (0.83–0.90) | 1,797 | 359 | 0.33 (0.32–0.35) | 4,042 | 808 | 0.51 (0.50–0.53) |
| Other neuroepithelial tumors | 26 | 5 | 0.01 (0.01-0.01) | 35 | 7 | 0.01 (0.00–0.01) | 43 | 9 | 0.01 (0.00–0.01) |
| Neuronal and Mixed Neuronal-Glial Tumors | 1,371 | 274 | 0.45 (0.43–0.47) | 2,069 | 414 | 0.38 (0.36–0.40) | 1,710 | 342 | 0.23 (0.22–0.24) |
| Malignant | 100 | 20 | 0.03 (0.03–0.04) | 203 | 41 | 0.04 (0.03–0.04) | 675 | 135 | 0.09 (0.08–0.09) |
| Non-Malignant | 1,271 | 254 | 0.42 (0.39–0.44) | 1,866 | 373 | 0.34 (0.33–0.36) | 1,035 | 207 | 0.14 (0.13–0.15) |
| Choroid Plexus Tumors | 369 | 74 | 0.12 (0.11–0.13) | 211 | 42 | 0.04 (0.03–0.04) | 267 | 53 | 0.03 (0.03–0.04) |
| Malignant | 102 | 20 | 0.03 (0.03–0.04) | -- | -- | -- | -- | -- | -- |
| Non-Malignant | 267 | 53 | 0.09 (0.08–0.10) | -- | -- | -- | -- | -- | -- |
| Tumors of the Pineal Region | 147 | 29 | 0.05 (0.04–0.06) | 290 | 58 | 0.05 (0.05–0.06) | 306 | 61 | 0.04 (0.04–0.05) |
| Malignant | 127 | 25 | 0.04 (0.03–0.05) | 166 | 33 | 0.03 (0.03-0.03) | 129 | 26 | 0.02 (0.01–0.02) |
| Non-Malignant | 20 | 4 | 0.01 (0.00–0.01) | 124 | 25 | 0.02 (0.02–0.03) | 177 | 35 | 0.02 (0.02–0.03) |
| Embryonal Tumors | 2,196 | 439 | 0.72 (0.69–0.75) | 760 | 152 | 0.14 (0.13–0.15) | 296 | 59 | 0.04 (0.04–0.05) |
| Medulloblastoma | 1,486 | 297 | 0.49 (0.46–0.51) | 635 | 127 | 0.11 (0.11–0.12) | 157 | 31 | 0.02 (0.02–0.03) |
| Primitive neuroectodermal tumors | 187 | 37 | 0.06 (0.05–0.07) | 79 | 16 | 0.01 (0.01–0.02) | 85 | 17 | 0.01 (0.01-0.01) |
| Atypical teratoid/rhabdoid tumor | 376 | 75 | 0.12 (0.11–0.14) | -- | -- | -- | -- | -- | -- |
| All other embryonal | 147 | 29 | 0.05 (0.04–0.06) | -- | -- | -- | -- | -- | -- |
| Tumors of Cranial and Paraspinal Nerves | 748 | 150 | 0.25 (0.23–0.26) | 5,530 | 1,106 | 1.06 (1.03–1.09) | 30,406 | 6,081 | 3.77 (3.73–3.82) |
| Nerve sheath tumors | 748 | 150 | 0.25 (0.23–0.26) | -- | -- | -- | 30,377 | 6,075 | 3.77 (3.73–3.81) |
| Malignant | -- | -- | -- | -- | -- | -- | 151 | 30 | 0.02 (0.02-0.02) |
| Non-Malignant | -- | -- | -- | -- | -- | -- | 30,226 | 6,045 | 3.75 (3.71–3.80) |
| Other tumors of cranial and paraspinal nerves | -- | -- | -- | -- | -- | -- | 29 | 6 | 0.00 (0.00–0.01) |
| Tumors of Meninges | 698 | 140 | 0.23 (0.21–0.25) | 11,414 | 2,283 | 2.24 (2.20–2.28) | 162,456 | 32,491 | 20.08 (19.98–20.18) |
| Meningiomas | 311 | 62 | 0.10 (0.09–0.11) | 9,772 | 1,954 | 1.93 (1.89–1.97) | 158,349 | 31,670 | 19.56 (19.46–19.66) |
| Malignant | 18 | 4 | 0.01 (0.00–0.01) | 115 | 23 | 0.02 (0.02–0.03) | 1,566 | 313 | 0.19 (0.18–0.20) |
| Non-Malignant | 293 | 59 | 0.10 (0.09–0.11) | 9,657 | 1,931 | 1.91 (1.87–1.95) | 156,783 | 31,357 | 19.37 (19.27–19.47) |
| Mesenchymal tumors | -- | -- | -- | -- | -- | -- | 4,003 | 801 | 0.51 (0.50–0.53) |
| Malignant | -- | -- | -- | -- | -- | -- | 522 | 104 | 0.07 (0.06–0.07) |
| Non-Malignant | -- | -- | -- | -- | -- | -- | 3,481 | 696 | 0.45 (0.43–0.46) |
| Primary melanocytic lesions | -- | -- | -- | -- | -- | -- | 104 | 21 | 0.01 (0.01–0.02) |
| Lymphomas and Hematopoietic Neoplasms | 88 | 18 | 0.03 (0.02–0.04) | 549 | 110 | 0.10 (0.10–0.11) | 7,921 | 1,584 | 0.96 (0.94–0.99) |
| Lymphoma | 88 | 18 | 0.03 (0.02–0.04) | -- | -- | -- | 7,848 | 1,570 | 0.96 (0.93–0.98) |
| Other hematopoietic neoplasms | -- | -- | -- | -- | -- | -- | 73 | 15 | 0.01 (0.01-0.01) |
| Germ Cell Tumors | 583 | 117 | 0.19 (0.18–0.21) | 602 | 120 | 0.11 (0.10–0.12) | 67 | 13 | 0.01 (0.01-0.01) |
| Malignant | 497 | 99 | 0.16 (0.15–0.18) | 563 | 113 | 0.10 (0.09–0.11) | 25 | 5 | 0.00 (0.00–0.01) |
| Non-Malignant | 86 | 17 | 0.03 (0.02–0.03) | 39 | 8 | 0.01 (0.01-0.01) | 42 | 8 | 0.01 (0.00–0.01) |
| Tumors of Sellar Region | 1,771 | 354 | 0.58 (0.56–0.61) | 22,908 | 4,582 | 4.28 (4.23–4.34) | 52,405 | 10,481 | 6.76 (6.70–6.82) |
| Tumors of the pituitary | 1,096 | 219 | 0.36 (0.34–0.38) | 22,200 | 4,440 | 4.15 (4.10–4.21) | 50,649 | 10,130 | 6.54 (6.48–6.60) |
| Malignant | -- | -- | -- | -- | -- | -- | 105 | 21 | 0.01 (0.01–0.02) |
| Non-Malignant | -- | -- | -- | -- | -- | -- | 50,544 | 10,109 | 6.52 (6.47–6.58) |
| Craniopharyngioma | 675 | 135 | 0.22 (0.21–0.24) | 708 | 142 | 0.13 (0.12–0.14) | 1,756 | 351 | 0.22 (0.21–0.23) |
| Unclassified Tumors | 1,098 | 220 | 0.36 (0.34–0.38) | 2,842 | 568 | 0.53 (0.51–0.55) | 14,857 | 2,971 | 1.86 (1.83–1.89) |
| Hemangioma | 294 | 59 | 0.10 (0.09–0.11) | 1,175 | 235 | 0.22 (0.21–0.23) | 2,672 | 534 | 0.35 (0.33–0.36) |
| Neoplasm, unspecified | 621 | 124 | 0.20 (0.19–0.22) | 1,544 | 309 | 0.29 (0.28–0.30) | 11,928 | 2,386 | 1.48 (1.45–1.51) |
| Malignant | 168 | 34 | 0.06 (0.05–0.06) | 346 | 69 | 0.07 (0.06–0.07) | 6,178 | 1,236 | 0.76 (0.74–0.78) |
| Non-Malignant | 453 | 91 | 0.15 (0.14–0.16) | 1,198 | 240 | 0.22 (0.21–0.24) | 5,750 | 1,150 | 0.72 (0.70–0.74) |
| All other | 183 | 37 | 0.06 (0.05–0.07) | 123 | 25 | 0.02 (0.02–0.03) | 257 | 51 | 0.03 (0.03–0.04) |
| Malignant | 57 | 11 | 0.02 (0.01–0.02) | -- | -- | -- | -- | -- | -- |
| Non-Malignant | 126 | 25 | 0.04 (0.03–0.05) | -- | -- | -- | -- | -- | -- |
| TOTAL e | 17,808 | 3,562 | 5.85 (5.76–5.93) | 62,558 | 12,512 | 11.82 (11.73–11.92) | 351,407 | 70,281 | 43.67 (43.53–43.82) |
| Malignant | 11,834 | 2,367 | 3.88 (3.82–3.96) | 17,364 | 3,473 | 3.25 (3.20–3.30) | 96,364 | 19,273 | 11.79 (11.72–11.87) |
| Non-Malignant | 5,974 | 1,195 | 1.96 (1.91–2.01) | 45,194 | 9,039 | 8.57 (8.49–8.65) | 255,043 | 51,009 | 31.88 (31.76–32.01) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cChildren as defined by the National Cancer Institute, see: http://www.cancer.gov/researchandfunding/snapshots/pediatric.
dAdolescents and Young Adults (AYA), as defined by the National Cancer Institute, see: http://www.cancer.gov/cancertopics/aya.
eRefers to all brain tumors including histologies not presented in this table.
-- Counts and rates are not presented when fewer than 16 cases were reported for the specific category. The suppressed cases are included in the counts and rates for totals.
Abbreviations: AYA, Adolescents and Young Adults; CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; CI, confidence interval; NOS, not otherwise specified